NCT05140863View on ClinicalTrials.gov

To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Postherpetic Neuralgia

PHASE3CompletedINTERVENTIONAL

Enrollment

372

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

December 22, 2022

Study Completion Date

January 5, 2023

Conditions

Postherpetic Neuralgia

Interventions

DRUG

HSK16149 20mg BID

HSK16149 20mg, orally twice a day, treatment period; 12-weeks fixed dose

DRUG

HSK16149 40mg BID

HSK16149 40mg, orally twice a day, treatment period; 12-weeks fixed dose

DRUG

Placebo BID

Placebo, orally twice a day, treatment period; 12-weeks fixed dose

Trial Locations (2)

210042

Dermatology Hospital of Chinese Academy of Medical Sciences, Nanjing

330006

The First Affiliated Hospital Of Nanchang University, Nanchang

All Listed Sponsors

lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY

NCT05140863 - To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Postherpetic Neuralgia | Biotech Hunter | Biotech Hunter